Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Family Member Incarceration, Psychological Stress, and Subclinical Cardiovascular Disease in Mexican Women (2012-2016).

Connors K, Flores-Torres MH, Stern D, Valdimarsdóttir U, Rider JR, Lopez-Ridaura R, Kirschbaum C, Cantú-Brito C, Catzin-Kuhlmann A, Rodriguez BL, Correa CP, Lajous M.

Am J Public Health. 2020 Jan;110(S1):S71-S77. doi: 10.2105/AJPH.2019.305397.

PMID:
31967877
2.

Impact of age at diagnosis of de novo metastatic prostate cancer on survival.

Bernard B, Burnett C, Sweeney CJ, Rider JR, Sridhar SS.

Cancer. 2019 Nov 26. doi: 10.1002/cncr.32630. [Epub ahead of print]

PMID:
31769876
3.

Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.

Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA.

Clin Cancer Res. 2019 Nov 21. doi: 10.1158/1078-0432.CCR-19-2853. [Epub ahead of print]

PMID:
31754047
4.

Observational Studies Have a Critical Role to Play in Cancer Comparative Effectiveness Research.

Rider JR, Trinquart L.

J Clin Oncol. 2019 Oct 10;37(29):2695-2696. doi: 10.1200/JCO.19.01043. Epub 2019 Aug 29. No abstract available.

PMID:
31465256
5.

Socioenvironmental adversity and risk of prostate cancer in non-Hispanic black and white men.

Kantor ED, Haneuse S, Valdimarsdóttir UA, Williams DR, Signorello LB, Rider JR.

Cancer Causes Control. 2019 Sep;30(9):997-1007. doi: 10.1007/s10552-019-01196-w. Epub 2019 Jul 1.

PMID:
31264140
6.

Restricted Mean Survival Times to Improve Communication of Evidence from Cancer Randomized Trials and Observational Studies.

Trinquart L, Bill-Axelson A, Rider JR.

Eur Urol. 2019 Aug;76(2):137-139. doi: 10.1016/j.eururo.2019.04.002. Epub 2019 Apr 26.

PMID:
31031048
7.

Review of the Neotropical genus Rhyncholepta with descriptions of three new species-group taxa (Hemiptera, Heteroptera, Pentatomidae).

Kment P, Eger JE, Rider JDA.

Zookeys. 2018 Nov 15;(796):347-395. doi: 10.3897/zookeys.796.22517. eCollection 2018.

8.

Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.

Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ.

Clin Genitourin Cancer. 2019 Feb;17(1):32-37. doi: 10.1016/j.clgc.2018.09.022. Epub 2018 Oct 4.

PMID:
30348512
9.

Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.

Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112.

10.

Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors.

DuPre NC, Flavin R, Sfanos KS, Unger RH, To S, Gazeeva E, Fiorentino M, De Marzo AM, Rider JR, Mucci LA; Transdisciplinary Prostate Cancer Partnership(ToPCaP).

Prostate. 2018 Nov;78(15):1172-1180. doi: 10.1002/pros.23692. Epub 2018 Jul 15.

11.

Regular aspirin use and gene expression profiles in prostate cancer patients.

Stopsack KH, Ebot EM, Downer MK, Gerke TA, Rider JR, Kantoff PW, Mucci LA.

Cancer Causes Control. 2018 Aug;29(8):775-784. doi: 10.1007/s10552-018-1049-5. Epub 2018 Jun 18.

12.

Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency.

Sinnott JA, Brumberg K, Wilson KM, Ebot EM, Giovannucci EL, Mucci LA, Rider JR.

Eur Urol. 2018 Nov;74(5):545-548. doi: 10.1016/j.eururo.2018.05.006. Epub 2018 May 18.

13.

High inducible nitric oxide synthase in prostate tumor epithelium is associated with lethal prostate cancer.

Erlandsson A, Carlsson J, Andersson SO, Vyas C, Wikström P, Andrén O, Davidsson S, Rider JR.

Scand J Urol. 2018 Apr;52(2):129-133. doi: 10.1080/21681805.2017.1421261. Epub 2018 Jan 8.

PMID:
29307261
14.

FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.

Davidsson S, Andren O, Ohlson AL, Carlsson J, Andersson SO, Giunchi F, Rider JR, Fiorentino M.

Prostate. 2018 Jan;78(1):40-47. doi: 10.1002/pros.23442. Epub 2017 Nov 6.

15.

Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.

Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA.

Cancer. 2017 Nov 1;123(21):4130-4138. doi: 10.1002/cncr.30831. Epub 2017 Jul 12.

16.

A Walking Intervention Among Men With Prostate Cancer: A Pilot Study.

Pernar CH, Fall K, Rider JR, Markt SC, Adami HO, Andersson SO, Valdimarsdottir U, Andrén O, Mucci LA.

Clin Genitourin Cancer. 2017 Dec;15(6):e1021-e1028. doi: 10.1016/j.clgc.2017.05.022. Epub 2017 May 31.

17.

Cholesterol uptake and regulation in high-grade and lethal prostate cancers.

Stopsack KH, Gerke TA, Andrén O, Andersson SO, Giovannucci EL, Mucci LA, Rider JR.

Carcinogenesis. 2017 Aug 1;38(8):806-811. doi: 10.1093/carcin/bgx058.

18.

Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer.

Giunchi F, Jordahl K, Bollito E, Colecchia M, Patriarca C, D'Errico A, Vasuri F, Malvi D, Fornari A, Bonetti LR, Corti B, Papotti M, DeGiuli P, Loda M, Montironi R, Fiorentino M, Rider JR.

Virchows Arch. 2017 Jun;470(6):711-715. doi: 10.1007/s00428-017-2123-1. Epub 2017 Apr 12.

PMID:
28405833
19.

The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies.

Pettersson A, Gerke T, Fall K, Pawitan Y, Holmberg L, Giovannucci EL, Kantoff PW, Adami HO, Rider JR, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Cancer. 2017 May 1;123(9):1490-1496. doi: 10.1002/cncr.30582. Epub 2017 Feb 2. Review.

20.

Perineural Invasion and Risk of Lethal Prostate Cancer.

Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):719-726. doi: 10.1158/1055-9965.EPI-16-0237. Epub 2017 Jan 6.

21.

The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.

Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA.

Cancer Metab. 2016 Dec 7;4:22. doi: 10.1186/s40170-016-0161-9. eCollection 2016.

22.

Sniffing out significant "Pee values": genome wide association study of asparagus anosmia.

Markt SC, Nuttall E, Turman C, Sinnott J, Rimm EB, Ecsedy E, Unger RH, Fall K, Finn S, Jensen MK, Rider JR, Kraft P, Mucci LA.

BMJ. 2016 Dec 13;355:i6071. doi: 10.1136/bmj.i6071.

23.

Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Sinnott JA, Peisch SF, Tyekucheva S, Gerke T, Lis R, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, Penney KL.

Clin Cancer Res. 2017 Jan 1;23(1):81-87. doi: 10.1158/1078-0432.CCR-16-1245. Epub 2016 Sep 23.

24.

Snus use, smoking and survival among prostate cancer patients.

Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, Adami HO, Stattin P, Nyrén O, Mucci LA.

Int J Cancer. 2016 Dec 15;139(12):2753-2759. doi: 10.1002/ijc.30411.

25.

Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men.

Sigurdardottir LG, Markt SC, Sigurdsson S, Aspelund T, Fall K, Schernhammer E, Rider JR, Launer L, Harris T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, Mucci LA.

J Biol Rhythms. 2016 Oct;31(5):461-9. doi: 10.1177/0748730416656948. Epub 2016 Jul 22.

26.

Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade.

Yang M, Zu K, Mucci LA, Rider JR, Fiorentino M, Clinton SK, Loda M, Stampfer MJ, Giovannucci E.

Cancer Causes Control. 2016 Aug;27(8):1043-7. doi: 10.1007/s10552-016-0782-x. Epub 2016 Jul 5.

27.

Erratum to: Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer.

Davidsson S, Mölling P, Rider JR, Unemo M, Karlsson MG, Carlsson J, Andersson SO, Elgh F, Söderquist B, Andrén O.

Infect Agent Cancer. 2016 Jun 21;11:36. doi: 10.1186/s13027-016-0084-7. eCollection 2016.

28.

Cholesterol Metabolism and Prostate Cancer Lethality.

Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR.

Cancer Res. 2016 Aug 15;76(16):4785-90. doi: 10.1158/0008-5472.CAN-16-0903. Epub 2016 Jun 20.

30.

Lead Time, Like Trains and Tides, Stops for No One.

Rider JR.

Eur Urol. 2017 Feb;71(2):202-203. doi: 10.1016/j.eururo.2016.06.003. Epub 2016 Jun 13. No abstract available.

PMID:
27311361
31.

Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer.

Davidsson S, Mölling P, Rider JR, Unemo M, Karlsson MG, Carlsson J, Andersson SO, Elgh F, Söderquis B, Andrén O.

Infect Agent Cancer. 2016 Jun 9;11:26. doi: 10.1186/s13027-016-0074-9. eCollection 2016. Erratum in: Infect Agent Cancer. 2016;11:36.

33.

Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer.

Börnigen D, Tyekucheva S, Wang X, Rider JR, Lee GS, Mucci LA, Sweeney C, Huttenhower C.

PLoS Comput Biol. 2016 Apr 14;12(4):e1004820. doi: 10.1371/journal.pcbi.1004820. eCollection 2016 Apr.

34.

Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up.

Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, Giovannucci EL.

Eur Urol. 2016 Dec;70(6):974-982. doi: 10.1016/j.eururo.2016.03.027. Epub 2016 Mar 28.

35.

Trichomonas vaginalis infection and risk of advanced prostate cancer.

Shui IM, Kolb S, Hanson C, Sutcliffe S, Rider JR, Stanford JL.

Prostate. 2016 May;76(7):620-3. doi: 10.1002/pros.23153. Epub 2016 Jan 28.

36.

Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.

Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA.

Am J Clin Nutr. 2016 Mar;103(3):851-60. doi: 10.3945/ajcn.115.118703. Epub 2016 Jan 27.

37.

Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort.

Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2016 Mar;37(3):262-8. doi: 10.1093/carcin/bgw001. Epub 2016 Jan 16.

38.

Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study.

Markt SC, Flynn-Evans EE, Valdimarsdottir UA, Sigurdardottir LG, Tamimi RM, Batista JL, Haneuse S, Lockley SW, Stampfer M, Wilson KM, Czeisler CA, Rider JR, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):302-8. doi: 10.1158/1055-9965.EPI-14-1274. Epub 2015 Dec 16.

39.

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.

J Natl Cancer Inst. 2015 Nov 27;108(2). pii: djv346. doi: 10.1093/jnci/djv346. Print 2016 Feb.

40.

Trouble in Paradise: Unmeasured Confounding in Registry-based Studies of Etiologic Factors.

Rider JR.

Eur Urol. 2016 May;69(5):883-4. doi: 10.1016/j.eururo.2015.10.044. Epub 2015 Nov 7. No abstract available.

PMID:
26559127
41.

Metformin and prostate cancer mortality: a meta-analysis.

Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL.

Cancer Causes Control. 2016 Jan;27(1):105-13. doi: 10.1007/s10552-015-0687-0. Epub 2015 Nov 4.

PMID:
26537119
42.

Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer.

Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing C, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An SS, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM.

Clin Cancer Res. 2016 Jan 15;22(2):448-58. doi: 10.1158/1078-0432.CCR-15-0256. Epub 2015 Oct 7.

43.

Correction: Cancer Incidence following Expansion of HIV Treatment in Botswana.

Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, Seage GR 3rd, Suneja G, Kayembe MK, Mmalane M, Rebbeck T, Rider JR, Essex M, Lockman S.

PLoS One. 2015 Sep 16;10(9):e0138742. doi: 10.1371/journal.pone.0138742. eCollection 2015. No abstract available.

44.

Cancer Incidence following Expansion of HIV Treatment in Botswana.

Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, Seage GR 3rd, Suneja G, Kayembe MK, Mmalane M, Rebbeck T, Rider JR, Essex M, Lockman S.

PLoS One. 2015 Aug 12;10(8):e0135602. doi: 10.1371/journal.pone.0135602. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0138742.

45.

Molecular differences in transition zone and peripheral zone prostate tumors.

Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson SO, Andrén O.

Carcinogenesis. 2015 Jun;36(6):632-8. doi: 10.1093/carcin/bgv051. Epub 2015 Apr 13.

46.

Tumor expression of adiponectin receptor 2 and lethal prostate cancer.

Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, Giovannucci EL, Loda M, Mucci LA, Finn S; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2015 Jun;36(6):639-47. doi: 10.1093/carcin/bgv048. Epub 2015 Apr 11.

47.

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.

Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA; Transdisciplinary Prostate Cancer Partnership ToPCaP.

Prostate. 2015 Jun 15;75(9):897-906. doi: 10.1002/pros.22973. Epub 2015 Mar 1.

48.

Circadian clock genes and risk of fatal prostate cancer.

Markt SC, Valdimarsdottir UA, Shui IM, Sigurdardottir LG, Rider JR, Tamimi RM, Batista JL, Haneuse S, Flynn-Evans E, Lockley SW, Czeisler CA, Stampfer MJ, Launer L, Harris T, Smith AV, Gudnason V, Lindstrom S, Kraft P, Mucci LA.

Cancer Causes Control. 2015 Jan;26(1):25-33. doi: 10.1007/s10552-014-0478-z. Epub 2014 Nov 12.

49.

Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.

Sigurdardottir LG, Markt SC, Rider JR, Haneuse S, Fall K, Schernhammer ES, Tamimi RM, Flynn-Evans E, Batista JL, Launer L, Harris T, Aspelund T, Stampfer MJ, Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, Mucci LA.

Eur Urol. 2015 Feb;67(2):191-4. doi: 10.1016/j.eururo.2014.07.008. Epub 2014 Aug 5.

50.

Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study.

Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, Giovannucci EL, Mucci LA.

J Clin Oncol. 2014 Sep 20;32(27):3033-8.

Supplemental Content

Loading ...
Support Center